Collective Health Inc., a San Francisco-based provider of healthcare benefits to employees, raised $280 million in Series F financing. Health Care Service Corp. led the round, which included additional support from DFJ Growth, Founders Fund, G Squared, Maverick Ventures, New Enterprise Associates, PFM Health Sciences, SoftBank Vision Fund 1 and others.
Vida Health, a San Francisco-based virtual-care platform that treats mental and physical conditions, scored $110 million in Series D funding led by General Atlantic. New investors Centene, AXA Venture Partners and Ardea Capital Partners also participated in the round, along with existing backers Ally Bridge Group, AME Cloud Ventures, Aspect Ventures, Canvas Ventures, NGP Capital and Workday Ventures.
Cellares Corp., a South San Francisco, Calif.-based startup that automates cell therapy manufacturing, secured $82 million in Series B financing. Decheng Capital and Eclipse Ventures co-led the investment, which included contributions from Skyviews Life Science and 8VC.
Esker Therapeutics, a South San Francisco, Calif.-based precision medicine company focused on the treatment of autoimmune disorders, launched with $70 million in Series A funding from Foresite Capital.
Headway, a New York-based startup that is building a national network of therapists who accept insurance, fetched $70 million in Series B funding, giving the company a $750 million valuation. Andreessen Horowitz led the round, with participation from Thrive Capital, GV and Accel. Scott Kupor, managing partner at Andreessen Horowitz, is joining Headway’s board.
Groups Recover Together, a Burlington, Mass.-based provider of opioid addiction recovery services, raised $60 million in Series C funding. Oak HC/FT led the round, which included support from existing investors Bessemer Venture Partners, Transformation Capital, RRE Ventures, Optum Ventures and Kaiser Permanente Ventures. Amar Kendale, chief product officer at Teladoc Health, will join the company’s board.
Oculis SA, a Switzerland-based developer of ophthalmic treatments, closed a $57 million Series C round. BVCF Management and Hyfinity Investments co-led the investment, which saw participation from VI Partners, Bay City Capital, Brunnur Ventures, Earlybird Venture Capital, funds managed by Tekla Capital Management, Pivotal bioVenture Partners, Nan Fung Life Sciences, Novartis Venture Fund and others. BVCF’s Vanessa Huang and Hyfinity’s Sylvia He will join the board.
ZOE, a London- and Boston-based startup providing individual guidance on what foods to eat to maximize long-term health, added $20 million in Series B funding. Ahren Innovation Capital led the investment, which included participation from Accomplice, Daphni and others.
Neuroelectrics, a Cambridge, Mass.- and Barcelona-based developer of brain stimulation technologies and therapies, grabbed $17.5 million in Series A financing led by Morningside Ventures.
BridGene Biosciences Inc., a Sunnyvale, Calif.-based startup developing small molecules that drug traditionally undruggable targets, snagged a $12 million Series A investment. Wedo Venture Partners led the round, and was joined by investors including Kaitai Capital and Takeda Ventures.
Little Otter, a San Francisco-based children's mental health startup, launched with $4.2 million in pre-seed and seed funding led by Torch Capital, Vast Ventures, Box Group, Canaan, 8VC and others.
|